6533b85ffe1ef96bd12c1017

RESEARCH PRODUCT

Randomized clinical study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region

Tibor BorsosMartin RöllinghoffJ. BierHerb J. RappHermann WagnerBert ZbarS. J. Kleinschuster

subject

Cancer Researchmedicine.medical_specialtyKidneybusiness.industryImmunologymedicine.diseasecomplex mixturesGastroenterologyPeripheral bloodSurgeryClinical studymedicine.anatomical_structureOncologyCancer remissionInternal medicinemedicineCarcinomaImmunology and AllergyIn patientBasal cellHead and neckbusinesshuman activities

description

Based on animal experiments a clinical study with BCG cell wall preparation (CWP) was developed. Patients with head and neck carcinomas stage T1/2N0–2M0 were randomized. One group received surgical treatment only and a second group received preoperative intralesional BCG-CWP. So far 12 patients have been included in each group. After 3 years the CCR (complete cancer remission) in the surgery only group was 39% and that in the preoperative BCG-CWP group, 69% (P=11%). The cumulative proportion of surviving patients was 50% in the surgery only and 73% in the BCG-CWP group (P=21%). BCG-CWP injection was followed by an increase in body temperature and a decrease in peripheral blood lymphocytes. No changes in liver, kidney, or other organ function could be observed after BCG-CWP therapy. Complications and severe secondary effects such as have been described for living BCG were not observed, and significant immunological changes have not been detected so far.

yearjournalcountryeditionlanguage
1981-12-01Cancer Immunology Immunotherapy
https://doi.org/10.1007/bf00200315